BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway
Background: Osteosarcoma, a tumor that originates from bone cells, has a poor prognosis and a high degree of malignancy. Anlotinib, a small-molecule multi-target tyrosine kinase inhibitor (TKI), is the first-line drug in treating osteosarcoma, especially in late-stage osteosarcoma. However, patients...
Main Authors: | Qingtao Meng, Jian Han, Peng Wang, Chenxu Jia, Mingyang Guan, Bolun Zhang, Wenzhi Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Journal of Bone Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137424000745 |
Similar Items
-
The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
by: Wang T, et al.
Published: (2022-10-01) -
Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells
by: Bingxin Zheng, et al.
Published: (2024-02-01) -
Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
by: Jiuhui Xu, et al.
Published: (2023-06-01) -
Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review
by: Qian Chen, et al.
Published: (2023-12-01) -
Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
by: Naveen Kumar Velayutham, et al.
Published: (2023-03-01)